Gamma Knife Market to Grow at 5.7% CAGR Through 2032, Says Persistence Market Research

The global gamma knife market represents a critical and fast-evolving segment within the advanced medical devices and neuro-oncology landscape. Gamma Knife technology, a form of stereotactic radiosurgery, delivers highly focused gamma radiation beams to treat brain tumors and complex neurological disorders without invasive surgery. Its ability to target lesions with sub-millimeter accuracy while preserving surrounding healthy tissue has made it an essential therapeutic modality for neurosurgeons and radiation oncologists worldwide. As healthcare systems increasingly prioritize minimally invasive treatments with faster recovery times and lower complication rates, gamma knife radiosurgery has emerged as a preferred alternative to conventional neurosurgical interventions.

Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/3742

From a market perspective, the global gamma knife market is likely to be valued at approximately US$468.0 million in 2025 and is projected to reach US$692.0 million by 2032, expanding at a compound annual growth rate (CAGR) of 5.7% during the forecast period. This steady growth trajectory is primarily driven by the rising prevalence of brain metastases, benign and malignant brain tumors, vascular malformations, and functional neurological disorders. Technological advancements such as AI-assisted dose planning, integrated MRI imaging, and robotic positioning systems are further accelerating adoption. High-end gamma knife systems dominate revenue generation, while hospitals remain the leading end-user segment due to their centralized infrastructure and reimbursement advantages.

North America currently holds a strong leadership position owing to favorable reimbursement policies, established healthcare infrastructure, and high awareness among clinicians. However, Asia Pacific has emerged as both the largest and fastest-growing regional market, accounting for nearly 33.0% share in 2025, supported by aggressive hospital expansion, rising cancer incidence, and strong public investment in medical technologies. The brain metastasis segment leads disease indications with over 60.0% market share, reflecting the increasing burden of advanced cancer cases globally and reinforcing the clinical importance of gamma knife technology.

Key Highlights from the Report

• The global gamma knife market is expected to grow from US$468.0 million in 2025 to US$692.0 million by 2032 at a CAGR of 5.7%.
• Brain metastasis dominates disease indications, accounting for more than 60.0% of total market revenue in 2025.
• High-end gamma knife systems contribute nearly 55.0% of the total revenue due to advanced imaging and AI integration.
• Asia Pacific is the largest and fastest-growing region, projected to register a CAGR of 9.6% through 2032.
• Hospitals remain the dominant end-user segment with close to 70.0% market share in 2025.
• Technological innovation and regulatory support are accelerating the shift from invasive neurosurgery to outpatient radiosurgery.

Market Statistics and Competitive Positioning

The gamma knife market has demonstrated consistent historical growth, with a CAGR of 5.8% between 2019 and 2024, highlighting sustained demand across both developed and emerging economies. Approximately 88,000 gamma knife procedures are performed annually worldwide, reflecting strong clinical acceptance and expanding procedural volumes. Cost-effectiveness has become a major factor influencing hospital adoption, as stereotactic radiosurgery can reduce hospital stays and post-operative care expenses by up to 15% per patient, improving both patient outcomes and provider margins.

The market is moderately consolidated, with the top manufacturers controlling nearly 70.0% of global revenue. Industry leaders focus on product innovation, clinical partnerships, and geographic expansion to maintain their competitive edge. Emerging players, particularly in Asia Pacific, are introducing cost-effective alternatives that appeal to mid-tier hospitals and specialty clinics, intensifying competition and improving accessibility.

Market Segmentation Analysis

The gamma knife market is segmented based on disease indication, device range, and end-user, each contributing uniquely to overall revenue growth. From a disease indication perspective, brain metastases represent the largest segment due to the high incidence of secondary brain tumors among cancer patients and the proven efficacy of gamma knife radiosurgery in managing multiple lesions simultaneously. Malignant and benign brain tumors, arteriovenous malformations, trigeminal neuralgia, epilepsy, and other functional neurological disorders form additional segments, with functional indications gaining traction as clinical evidence expands.

Based on device range, high-end gamma knife systems dominate the market, accounting for nearly 55.0% of total revenue in 2025. These systems are equipped with integrated MRI, advanced dose-planning software, and AI-driven targeting capabilities, enabling higher patient throughput and superior clinical outcomes. Medium-range systems are witnessing faster adoption, particularly in emerging markets, as they offer a balance between affordability and technological sophistication. Entry-level systems, although limited in features, play a role in expanding access in cost-sensitive regions.

In terms of end-users, hospitals remain the primary adopters, holding close to 70.0% market share. Large tertiary care centers and academic hospitals are investing in gamma knife systems to enhance their neuro-oncology service portfolios. Ambulatory surgical centers and specialty clinics represent the fastest-growing end-user segment, supported by the global shift toward outpatient care models and regulatory flexibility in minimally invasive procedures.

Get Custom Insights Designed for Your Business: https://www.persistencemarketresearch.com/request-customization/3742

Regional Insights into the Gamma Knife Market

North America continues to maintain a dominant position in the global gamma knife market, accounting for approximately 31.0% market share in 2025, driven by robust reimbursement frameworks, advanced healthcare infrastructure, and strong research and development activity. The United States leads regional adoption due to high cancer prevalence, extensive clinical trials, and the presence of major manufacturers. Favorable Medicare and Medicaid reimbursement policies for stereotactic radiosurgery further support market expansion.

Europe represents a significant share of the global market, with countries such as Germany, the United Kingdom, France, and Spain leading adoption. The region benefits from universal healthcare coverage, strong public funding, and regulatory harmonization under the European Medicines Agency. Fragmented competition allows regional players and specialty clinics to coexist with global manufacturers, while cross-border collaborations and mergers support technological diffusion.

Asia Pacific has emerged as the largest and fastest-growing regional market, capturing nearly 33.0% share in 2025. Rapid hospital construction, rising healthcare expenditure, and increasing awareness of advanced neurological treatments are driving demand across China, Japan, India, and Southeast Asia. Government-backed healthcare reforms and streamlined regulatory approvals in countries such as Japan and Singapore are accelerating device installations. The presence of domestic manufacturers alongside global players is intensifying competition and improving affordability.

Market Drivers

Technological advancements remain the most influential driver of growth in the gamma knife market. Continuous innovation in imaging integration, AI-powered dose planning, and robotic positioning has significantly improved treatment accuracy, safety, and efficiency. These advancements enable clinicians to treat complex and previously inoperable brain lesions with minimal risk, reinforcing the clinical preference for gamma knife radiosurgery over conventional surgical approaches.

The rising prevalence of brain tumors and neurological disorders is another major growth driver. Global cancer incidence continues to increase, with brain metastases becoming more common due to improved survival rates in primary cancers. Aging populations further contribute to higher rates of neurological conditions such as trigeminal neuralgia and vascular malformations, expanding the patient pool for gamma knife procedures.

Regulatory support and reimbursement expansion also play a crucial role in market growth. Fast-track approvals by regulatory agencies and favorable insurance coverage in high-income economies have improved accessibility and encouraged hospitals to invest in advanced radiosurgical technologies. Public and private investments in healthcare infrastructure, particularly in Asia Pacific and North America, further strengthen market momentum.

Market Restraints

Despite its clinical advantages, the gamma knife market faces significant restraints related to high capital costs. A single gamma knife system can cost upwards of US$4 million, excluding facility retrofitting, maintenance, and staff training expenses. These high upfront investments extend the return-on-investment period and limit adoption among smaller hospitals and clinics, particularly in emerging economies.

Regulatory complexity and workforce shortages also constrain market growth. Stringent approval requirements can delay product launches by several years, while the shortage of trained neurosurgeons and radiation oncologists limits procedural capacity. In certain regions, underutilization of installed systems remains a challenge, reducing operational efficiency and slowing revenue realization.

Market Opportunities

Emerging markets present substantial growth opportunities for gamma knife manufacturers. Expanding healthcare infrastructure, government-backed technology adoption programs, and rising cancer awareness in Asia Pacific are expected to generate significant incremental revenue through 2032. Tier-2 and Tier-3 cities represent untapped potential as private hospital networks expand their specialty care offerings.

Integration with advanced imaging and AI technologies offers another major opportunity. MRI-guided radiosurgery and real-time dose optimization can further improve clinical outcomes and increase procedural volumes. Manufacturers that successfully integrate these technologies can differentiate their offerings and justify premium pricing.

Unmet needs in pediatric and rare neurological disorders also represent a promising opportunity. Targeted investments in specialized gamma knife centers and policy support for pediatric radiosurgery could unlock new revenue streams while addressing critical gaps in care.

Checkout Now & Download Complete Market Report: https://www.persistencemarketresearch.com/checkout/3742

Company Insights

The global gamma knife market is served by a mix of established multinational corporations and emerging regional players, each contributing to technological innovation and market expansion.

• Elekta AB
• Varian Medical Systems
• Nordion Inc.
• Huiheng Medical, Inc.
• ET Medical Group
• American Shared Hospital Services
• Masep Infini Global, Inc.
• Hokai Medical Technology
• Cyber Medical Corporation Ltd.
• Accuray Incorporated
• Brainlab AG
• Elekta Korea Ltd.
• ZAP Surgical Systems Inc.
• IntraOp Medical Corporation
• Stryker Corporation

Market Segmentation

By Device Range

High-End Gamma Knife
Medium Gamma Knife
Low Gamma Knife

By Disease Indication

Brain Metastasis
Arteriovenous Malformation (AVM)
Malignant & Benign Tumors
Trigeminal Neuralgia
Vascular Disorders
Ocular Diseases
Others

By End-user

Hospitals
Ambulatory Service Centers
Specialty Clinics

By Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Rest of Europe
East Asia
China
Japan
South Korea
South Asia & Oceania
India
Southeast Asia
Australia & New Zealand
Rest of SEO
Latin America
Brazil
Mexico
Rest of LA
Middle East & Africa
GCC Countries
South Africa
Northern Africa
Rest of MENA

Recent developments in the market highlight ongoing innovation and expansion. In July 2025, Elekta received U.S. FDA 510(k) clearance for its Leksell Gamma Knife system to treat drug-resistant mesial temporal lobe epilepsy, significantly broadening its clinical application. In May 2025, AIIMS Delhi successfully utilized gamma knife radiosurgery to treat pediatric retinoblastoma for the first time in India, demonstrating the technology's expanding role in rare and pediatric indications.

Conclusion

The gamma knife market is positioned for steady and sustainable growth, driven by rising neurological disease prevalence, technological innovation, and the global shift toward minimally invasive treatments. While high capital costs and regulatory challenges remain barriers, expanding opportunities in emerging markets, advanced imaging integration, and specialty indications are expected to offset these constraints. With Asia Pacific emerging as the growth engine and continued innovation from leading manufacturers, gamma knife radiosurgery will remain a cornerstone of advanced neuro-oncology and functional neurosurgery over the coming decade.

Read More Related Reports:

Dysphagia Diet Thickening Agents Market https://www.persistencemarketresearch.com/market-research/dysphagia-diet-thickening-agents-market.asp
Cosmetic Procedures Market https://www.persistencemarketresearch.com/market-research/cosmetic-procedures-market.asp
Healthcare Quality Management Market https://www.persistencemarketresearch.com/market-research/healthcare-quality-management-market.asp
In Vitro Toxicology Testing Market https://www.persistencemarketresearch.com/market-research/in-vitro-toxicology-testing-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.